BIOPHARMA
By
Did Merck’s 2025 Strategies, Deals, and Pipeline Strength Position It for Breakthrough Growth in 2026?
Merck concluded 2025 with a strong performance across its pharmaceuticals, vaccines, and oncology segments, demonstrating resilience, strategic focus,…
Did AstraZeneca’s 2025 Deals Lay the Groundwork for Transformative Growth Across Oncology, Immunology, and Rare Diseases in 2026?
In 2025, AstraZeneca executed a series of strategic collaborations, partnerships, and selective acquisitions designed to strengthen its pipeline,…
Can AstraZeneca’s 2025 Execution Propel It to Leadership Across Oncology, CVRM, and Immunology in 2026?
AstraZeneca concluded 2025 as a company demonstrating resilient performance, focused execution, and continued innovation across its pharmaceuticals and…
How Did Sanofi’s 2025 Deals Shape Its Strategy and What Do They Mean for the Future?
In 2025, Sanofi pursued a series of strategic collaborations, acquisitions, and licensing agreements aimed at strengthening its core…
Can AstraZeneca’s 2025 Launches and Approvals Strengthen Its Oncology, Cardiovascular, and Respiratory Leadership Into 2026?
Global | January 2026 — AstraZeneca PLC achieved significant milestones in 2025, marked by multiple regulatory approvals, label…
Can Novo Nordisk’s 2025 Diabetes, Obesity, and Rare Disease Launches Drive Sustainable Growth Into 2026?
Global | January 2026 — Novo Nordisk A/S continued to reinforce its leadership in diabetes, obesity, and rare…
